Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86

Blood

Volumn 84, Issue 9, 1994, Pages 3122-3133

  Reiter, Alfred ^a   Schrappe, Martin ^b   Ludwig, Wolf Dieter ^b   Hiddemann, Wolfgang ^b   Sauter, Siegfried ^b   Henze, Günter ^b   Zimmermann, Martin ^b   Lampert, Fritz ^b   Havers, Werner ^b   Niethammer, Dietrich ^b   Odenwald, Edelgard ^b   Ritter, Jörg ^b   Mann, Georg ^b   Weite, Karl ^b   Gadner, Helmut ^b   Riehm, Hansjörg ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISONE; TENIPOSIDE; TIOGUANINE; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; DRUG RESPONSE; FEMALE; HUMAN; INFANT; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT PLANNING;

EID: 0028152851     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v84.9.3122.3122     Document Type: Article

References (45)

1. Riehm H, Gadner H, Henze G, Langermann HJ, Odenwald E: The Berlin childhood acute lymphoblastic leukemia therapy study, 1970-1976. Am J Pediatr Hematol Oncol 2:299, 1980
2. Riehm H, Feickert HJ, Schrappe M, Henze G, Schellong G: Therapy results in five ALL-BFM studies since 1970. Implications of risk factors for prognosis. Haematol Blood Transfus 30:139, 1987
3. Henze G, Langermann HJ, Ritter J, Schellong G, Riehm H: Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia: A report from the BFM study group. Haematol Blood Transfus 26:87, 1981
4. Langermann HJ, Henze G, Wulf M, Riehm H: Abschätzung der Tumorzellmasse bei der akuten lymphoblastischen Leukämie im Kindesalter: Prognostische Bedeutung und praktische Anwendung. Klin Pädiat 194:209, 1982
5. Jacquillat C, Weil M, Gemon MF: Combination therapy in 130 patients with acute lymphoblastic leukemia (Protocol 06 LA 66-Paris). Cancer Res 33:3278, 1973
6. Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein V, Ludwig R, Ritter J, Stollmann B, Henze G: Die Corticosteroidabhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83). Klin Pädiat 199:151, 1987
7. Herzig R, Wolff S, Lazarus H, Phillips G, Karanes C, Herzig G: High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62:361, 1983
8. Rodriquez V, McCredie KB, Keating MJ, Valdivieso M, Bodey GP, Freireich EJ: Ifosfamide therapy for hematologic malignancies in patients refractory to prior treatment. Cancer Treat Rep 62:493, 1978
9. Patte C, Bernard A, Hartmann O, Kalifa C, Flamant F, Lemerle J: High-dose Methotrexate and Continuous Infusion Ara-C in Children's Non-Hodgkin's Lymphoma: Phase II Studies and Their Use in Further Protocols. Pediatr Hematol Oncol 3:11, 1986
10. Paciucci PA, Cuttner J, Holland JF: Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. Semin Oncol 11:36, 1984 (suppl 3)
11. Riehm H, Gadner H, Henze G, Kornhuber B, Lampert F, Niethammer D, Reiter A, Schellong G: Results and Significance of Six Randomized Trials in Four Consecutive ALL-BFM Studies. Haematol Blood Transfus 33:439, 1990
12. Reiter A, Schrappe M, Ludwig WD, Lampert F, Harbott J, Henze G, Niemeyer CM, Gadner H. Müller-Weihrich S, Ritter J, Odenwald E, Riehm H: Favorable Outcome of B-Cell Acute Lymphoblastic Leukemia in Childhood: A Report of Three Consecutive Studies of the BFM Group. Blood 80:2471, 1992
13. Bennett JM, Catovski D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33:451, 1976
14. Ludwig WD, Bartram CR, Ritter J, Raghavachar A, Hiddemann W, Heil G, Harbott J, Seibt-Jung H, Teichmann JV, Riehm H: Ambiguous phenotypes and genotypes in 16 children as characterized by multiparameter analysis. Blood 71:1518, 1988
15. Harbott J, Ritterbach J, Ludwig W-D, Bartram CR, Reiter A, Lampert F: Clinical Significance of Cytogenetic Studies in Childhood Acute Lymphoblastic Leukemia: Experience of the BFM Trials. Recent Results in Cancer Res 131:123, 1993
16. Hiddemann W, Wömann B, Ritter J, Thiel E, Göhde W, Lahme B, Henze G, Schellong G, Riehm H, Büchner Th: Frequency and Clinical Significance of DNA Aneuploidy in Acute Leukemia. Ann N J Acad Sci 468:227, 1986
17. Look AT, Roberson PK, Williams DL, Rivera G, Bowman WP, Pui CH, Ochs J, Abromowitch J, Kalwinsky D, Dahl GV, George S, Murphy SB: Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia. Blood 65:1079, 1985
18. Casagrande JT, Pike MC, Smith PG: An improved approximate formula for calculating sample sizes for comparing two binominal distributions. Biometrics 34:483, 1978
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
20. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966
21. Cox DR: Regression models and life tables. J R Stat Soc 34:187, 1972
22. Bernstein D, Lagakos W: Sample Size and power determination for stratified clinical trials. J Statist Comput Sinn 8:65, 1978
23. Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE: Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/ Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 12:740, 1994
24. Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman P, Miller DR, Reaman G, Sather H, Hammond GD: Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 18:273, 1990
25. Pieters R, Huismans DR, Loonen AH, Hahlen K, van der Does-van den Berg A, van Wering ER, Veerman AJR: Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 338:399, 1991
26. Kato GJ, Quddus FF, Shuster JJ, Boyet J, Pullen JD, Borowitz MJ, Whitehead VM, Crist WM, Leventhal BG: High glucocorticoid receptor content of leukemic blasts is a favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood 82:2304, 1993
27. Trueworthy R, Shuster J, Look T, Crist W, Borowitz M, Carroll A, Frankel L, Harris M, Wagner H, Haggard M, Mosijczuk A, Pullen J, Steuber P, Land V: Ploidy of Lymphoblasts Is the Strongest Predictor of Treatment Outcome in B-Progenitor Cell Acute Lymphoblastic Leukemia of Childhood: A Pediatric Oncology Group Study. J Clin Oncol 10:606, 1992
28. Moe PJ, Seip M, Finne PH, Kolmannskog S: Methotrexate infusions in poor prognosis acute lymphoblastic leukemia in children: I. The Norwegian methotrexate study in acute lymphoblastic leukemia in childhood, August 1975-December 1980. Med Pediatr Oncol 14:187, 1986
29. Cassidy J, Merrick MV, Smyth JF, Leonard RCF: Cardiotoxicity of mitoxantrone assessed by stress and resting nuclear ventriculography. Eur J Cancer Clin Oncol 24:935, 1988
30. 2 methotrexate. Eur J Cancer 26:492, 1990
31. Hryniuk WM, Bertino JR: Treatment of leukemia with large doses of methotrexate and folinic acid: Clinical-biochemical correlates. J Clin Invest 48:2140, 1969
32. Ochs JJ: Neurotoxicity Due to Central Nervous System Therapy for Childhood Leukemia. Am J Ped Oncol 11:93, 1989 (suppl 1)
33. Siimes MA, Lie SO, Andersen O, Marky I, Rautonen J, Hertz H: Prophylactic Cranial Irradiation Increases the Risk of Testicular Damage in Adult Males Surviving ALL in Childhood. Med Ped Oncol 21:117, 1993
34. Nygaard R, Garwicz S, Haldorsen T, Hertz H, Jonmundsson GK, Lanning M, Moe PJ: Second malignant neoplasms in patients treated for childhood leukemia. A population-based cohort study from the Nordic countries. The Nordic Society of Pediatric Oncology and Hematology (NOPHO). Acta Paediatr Scand 80:1220, 1991
35. Niemeyer CM, Gelber RD, Tarbell NJ, Donnelly M, Clavell LA, Blattner SR, Donahue K, Cohen HJ, Sallan SE: Low-Dose Versus High-Dose Methotrexate During Remission Induction in Childhood Acute Lymphoblastic Leukemia (Protocol 81-01 Update). Blood 78:2514, 1991
36. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui CH, Abromowitch M, Mirro J Jr, Ochs JS, Look AT, Williams DL, Murphy SB, Dahl GV, Kalwinsky DK, Evans WE, Kun LE, Simone JV, Crist WM: Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337:61, 1991
37. Chessells JM, Bailey CC, Richards S: MRC UKALL X. The UK protocol for childhood ALL: 1985-1990. Leukemia 6:157, 1992 (suppl 2)
38. Tubergen DG, Gilchrist GS, O'Brien RTO, Coccia PF, Sather HN, Waskerwitz MJ, Hammond GD: Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Childrens Cancer Group phase III trial. J Clin Oncol 11:527, 1993
39. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808, 1991
40. Crist W, Carroll A, Shuster J, Jackson J, Head D, Borowitz M, Behm FG, Link M, Steuber P, Ragab A, Hirt A, Brock B, Land V, Pullen J: Philadelphia Chromosome Positive Childhood Acute Lymphoblastic Leukemia: Clinical and Cytogenetic Characteristics and Treatment Outcome. A Pediatric Oncology Group Study. Blood 76:489, 1990
41. Crist W, Shuster J, Look T, Borowitz M, Behm F, Bowman P, Frankel L, Pullen J, Krance R, Steuber P, Camitta B, Amylon M, Link M, Land V: Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. Leukemia 6:162, 1992 (suppl 2)
42. Veerman AJP, Hählen K, Kamps WA, Vanleeuwen EF, de Vaan GAM, Vanwering ER, van der Does-van den Berg A, Solbu G, Suciu S: Dutch Childhood Leukemia Study Group: Early Results of Study ALL VI (1984-1988). Haematol Blood Transfus 33:473, 1990
43. Whitehead VM, Vuchich MJ, Lauer SJ, Mahoney D, Carroll AJ, Shuster JJ, Esseltine DW, Payment C, Look AT, Akabutu J, Bowen T, Taylor LD, Camitta B, Pullen DJ: Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B lineage acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Blood 80:1316, 1992
44. Harris MB, Shuster JJ, Carroll A, Look AT, Borowitz MJ, Crist WM, Nitschke R, Pullen J, Steuber CP, Land VJ: Trisomy of Leukemic Cell Chromosomes 4 and 10 Identifies Children With B-Progenitor Cell Acute Lymphoblastic Leukemia With a Very Low Risk of Treatment Failure: A Pediatric Oncology Group Study. Blood 79:3316, 1992
45. Arthur DC, Bloomfield CD, Lindquist LL, Nesbit ME: Trans-location 4; 11 in acute lymphoblastic leukaemia: Clinical characteristics and prognostic significance. Blood 59:96, 1982